Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Thill

Showing results (61-70 of 165) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgeryJana Barinoff, Marcus Schmidt, Andreas Schneeweiss, et al.
Anticancer Research|July 23, 2011
Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodesHolm Eggeman, Frank Stöblen, Marc Thill, et al.
Journal of Surgical Oncology|November 1, 2021
Magnetic resonance imaging system for intraoperative margin assessment for DCIS and invasive breast cancer using the ClearSight™ system in breast-conserving surgery-Results from a postmarketing studyMarc Thill, Iris Szwarcfiter, Katharina Kelling, et al.
Breast Cancer Research and Treatment|September 12, 2022
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)Marc Thill, Pauline Wimberger, Andrea Grafe, et al.
Anticancer Research|January 4, 2012
Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cellsMarc Thill, Friederike Hoellen, Steffi Becker, et al.
Geburtshilfe Und Frauenheilkunde|June 21, 2019
Surgical Studies of Reconstructive Breast Surgery - An Overview of the Topics at the 2019 Annual Meeting of the Working Group for Reconstructive Surgery in Oncology-GynecologyStefan Paepke, Marion Kiechle, Christine Ankel, et al.
The Oncologist|May 7, 2026
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.
Geburtshilfe Und Frauenheilkunde|January 30, 2018
Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?Hannah Richter, André Hennigs, Benedikt Schaefgen, et al.
Anticancer Research|July 23, 2011
The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancerSolveig Landt, Harald Heidecke, Cora Reuter, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
Pageof 17

Showing results (61-70 of 165) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgeryJana Barinoff, Marcus Schmidt, Andreas Schneeweiss, et al.
Anticancer Research|July 23, 2011
Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodesHolm Eggeman, Frank Stöblen, Marc Thill, et al.
Journal of Surgical Oncology|November 1, 2021
Magnetic resonance imaging system for intraoperative margin assessment for DCIS and invasive breast cancer using the ClearSight™ system in breast-conserving surgery-Results from a postmarketing studyMarc Thill, Iris Szwarcfiter, Katharina Kelling, et al.
Breast Cancer Research and Treatment|September 12, 2022
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)Marc Thill, Pauline Wimberger, Andrea Grafe, et al.
Anticancer Research|January 4, 2012
Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cellsMarc Thill, Friederike Hoellen, Steffi Becker, et al.
Geburtshilfe Und Frauenheilkunde|June 21, 2019
Surgical Studies of Reconstructive Breast Surgery - An Overview of the Topics at the 2019 Annual Meeting of the Working Group for Reconstructive Surgery in Oncology-GynecologyStefan Paepke, Marion Kiechle, Christine Ankel, et al.
The Oncologist|May 7, 2026
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.
Geburtshilfe Und Frauenheilkunde|January 30, 2018
Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?Hannah Richter, André Hennigs, Benedikt Schaefgen, et al.
Anticancer Research|July 23, 2011
The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancerSolveig Landt, Harald Heidecke, Cora Reuter, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
Pageof 17